Evidence map›Paper›PMID 11511022›Full record

ReviewDrugs2001

Urinary tract infections in patients with spinal cord lesions: treatment and prevention.

F Biering-Sørensen, P Bagi, N Høiby

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07355803 (EVA-study on Catheter Selection Criteria at Start of Self-catheterization), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07355803 naterminatednot on this mapstarted 2025, after this paper: background citation

EVA-study on Catheter Selection Criteria at Start of Self-catheterization

TypeinterventionalSponsorColoplast NV/SARan2025 to 2026Enrolled22ConditionsNeurogenic Bladder Disorder, Non-Neurogenic Bladder, Bladder Dysfunction, Urinary RetentionArmsQuestionnaires : Patient questionnaire on catheter use and satisfaction, IC-Di-Q, and I-CAT
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Community-Acquired Urinary Tract Infection byBioMed research international · 2018
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. UTIs in patients with neurogenic bladder.Current urology reports · 2014
    Review
  17. Article
  18. Article
  19. Urinary tract infections in patients with spinal cord injuries.Current infectious disease reports · 2011
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

F Biering-SørensenClinic for Para- and Tetraplegia, Copenhagen University Hospital, Rigshospitalet, Denmark. finbs@rh.dk
P Bagi
N Høiby
Copenhagen University Hospital · DKCenter for Neurosciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even though the mortality due to urinary tract complications has decreased dramatically during the last decades in individuals with spinal cord lesions (SCL), urinary tract infections (UTI) still cause significant morbidity in this population. Complicated UTI are caused by a much wider variety of organisms in individuals with SCL than in the general population and are often polymicrobial. Escherichia coli, Pseudomonas spp., Klebsiella spp., Proteus spp., Serratia spp., Providencia spp., enterococci, and staphylococci are the most frequently isolated bacteria in urine specimens taken from individuals with SCL. There is no doubt that the greatest risk for complicated UTI in these individuals is the use of an indwelling catheter. Intermittent catheterisation during the rehabilitation phase has been shown to lower the rate of UTI, and virtually eliminate many of the complications associated with indwelling catheters. Persons with SCL should only be treated for bacteriuria if they have symptoms. Generally, it is advisable to use antibacterial agents with little or no impact on the normal flora. Single agent therapy - in accordance with antimicrobial susceptibility test - is preferred. We advise extending treatment to at least 5 days, and in those with reinfection or relapsing UTI, at least 7 to 14 days, depending on the severity of the infection. The diagnosis of structural and/or functional risk factors is essential in order to plan an optimal treatment for UTI in individuals with SCL, which should include treatment of simultaneously occurring predisposing factors. The treatment of structural risk factors follows general urological principles, aiming for sufficient outlet from the bladder with minimal residual urine and low pressure voiding. For prevention of UTI, general cleanliness and local hygiene should be encouraged. If the patient has a reinfection or relapsing symptomatic UTI, it is important to check for inadequately treated infection and complications, which need special attention, in particular residual urine and urinary stones. No reliable evidence exists of the effectiveness of cranberry juice and other cranberry products. Prophylactic antibacterials should only be used in patients with recurrent UTI where no underlying cause can be found and managed, and in particular if the upper urinary tract is dilated. Antibacterials should not be used for the prevention of UTI in individuals with SCL and indwelling catheters. However, the use of prophylactic antibacterials for individuals with SCL using intermittent catheterisation or other methods of bladder emptying is controversial.

Indexed as

Anti-Bacterial AgentsAnti-Infective Agents, UrinaryBacteriuriaHumansSpinal Cord InjuriesUrinary CatheterizationUrinary Tract InfectionsAnti-Bacterial AgentsAnti-Infective Agents, Urinary

Identifiers

PMID11511022
OpenAlexW2076588156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.